Bispecific anti-CD206 and CXCR4 glycopeptide for postoperative bladder cancer

A bispecific glycopeptide that simultaneously targets the chemokine receptor CXCR4 on tumor cells and the mannose receptor CD206 on tumor-associated macrophages could help treat recurrent forms of bladder cancer by decreasing metastasis and promoting T cell infiltration into tumors.

The compound links a CD206-targeting mannose group with a CXCR4-targeting peptide motif connected to a self-assembly domain; when the linker is cleaved by the protease MMP2 in the tumor microenvironment, the CXCR4-targeting peptides assemble into a tumor cell-targeting nanofiber. In a human bladder cancer cell line, the compound decreased tumor cell proliferation and migration. ...